Ferlito S, Bonomo T, Costa R, Di Salvo M M, Attanasio L, Finocchiaro P M, Condorelli M, Mazzone D
Cattedra di Semeiotica e Metodologia Medica, Università degli Studi, Catania.
Minerva Cardioangiol. 1996 Dec;44(12):645-8.
The authors analyse the short-term and medium-term effects of iloprost prostanoid derivate on hemostatic status in a group of patients with obliterating vascular disease of the lower limbs. The study included 10 patients (6 males, 4 females; aged 52 + 5 years old) suffering from Fontaine's stage 3 obstructive arterial disease. After a 10-hour fast each patient received a 6-hour iv infusion of iloprost at a dose of 2 ng/kg/min (approx 50 gamma) a venous blood sample was collected before and after infusion. The test was repeated using the same method after 4 weeks of treatment with the same dose of the drug. The following parameters were analysed in serum: fibrinogen (F) (IL coagulometric method), Factor VII (F VII) (IL coagulometric method), antithrombin II (AT III) (IL chromogenic method), protein C (PC) II coagulometric method) and protein S (PS) (IL coagulometric method). After the first infusion a significant increase was observed in AT III (p > 0.05), whereas other indices showed no significant variations. After treatment for 4 weeks AT III was again enhanced after infusion (p > 0.05); with regard to the basal values of other parameters, a significant reduction (p > 0.05) was found in F VII, whereas no other significant changes were observed. In the light of these results the authors suggest an antithrombotic effect of the drug documented by the short-term increase in AT III probably due to lower consumption, and a medium-term reduction in F VII due to trophic effect of the drug at a vasculoparietal level resulting in the depression of FVII tissue activation factors.
作者分析了伊洛前列素（一种前列腺素衍生物）对一组下肢血管闭塞性疾病患者止血状态的短期和中期影响。该研究纳入了10例患者（6例男性，4例女性；年龄52±5岁），均患有Fontaine 3期阻塞性动脉疾病。每位患者在禁食10小时后，接受6小时静脉输注伊洛前列素，剂量为2 ng/kg/min（约50微克），输注前后采集静脉血样。在使用相同剂量药物治疗4周后，采用相同方法重复该试验。分析血清中的以下参数：纤维蛋白原（F）（IL凝固法）、凝血因子VII（F VII）（IL凝固法）、抗凝血酶III（AT III）（IL发色法）、蛋白C（PC）（IL凝固法）和蛋白S（PS）（IL凝固法）。首次输注后，AT III显著升高（p>0.05），而其他指标无显著变化。治疗4周后，输注后AT III再次升高（p>0.05）；关于其他参数的基础值，F VII显著降低（p>0.05），而未观察到其他显著变化。根据这些结果，作者认为该药物具有抗血栓形成作用，短期AT III升高可能是由于消耗减少所致，而中期F VII降低是由于药物在血管壁水平的营养作用导致FVII组织激活因子降低。
